Compare Wahed FTSE USA Shariah ETF (HLAL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Novo Nordisk A/S — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.22, while Novo Nordisk A/S trades at $49.37 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| HLAL | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $71.70 |
52-Week Low | $54.05 | $35.29 |
Market Cap | — | $220.53B |
Enterprise Value | — | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, reflecting modest near-term pressure. Key financial ratios such as P/E, P/S, and ROE are not available in the current dataset, limiting fundamental visibility. A dividend of $0.02 is scheduled for June 2026, indicating a long-term income component. Trading volume and technical levels require additional market data for full context.
The outlook for HLAL hinges on upcoming financial disclosures to assess valuation and profitability. Investment opportunity lies in potential earnings growth and dividend yield, but risks include lack of current fundamental data and market volatility. Investors should await SEC filings for a clearer picture of the company's financial health.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
